Karla Hernandez-Villafuerte
Overview
Explore the profile of Karla Hernandez-Villafuerte including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
144
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ubels J, Hernandez-Villafuerte K, Niebauer E, Schlander M
Health Care Anal
. 2024 Aug;
PMID: 39158650
Developing an instrument with the capability approach can be challenging, since the capability concept of Sen is ambiguous concerning the burdens that people experience whilst achieving their capabilities. A solution...
2.
Muchadeyi M, Hernandez-Villafuerte K, Di Tanna G, Eckford R, Feng Y, Meregaglia M, et al.
Pharmacoeconomics
. 2024 Mar;
42(7):767-782.
PMID: 38551803
Background: The increasing number of studies that generate health state utility values (HSUVs) and the impact of HSUVs on cost-utility analyses make a robust tailored quality appraisal (QA) tool for...
3.
Schlander M, van Harten W, Retel V, Pham P, Vancoppenolle J, Ubels J, et al.
Lancet Oncol
. 2024 Mar;
25(4):e152-e163.
PMID: 38547899
Loss of income and out-of-pocket expenditures are important causes of financial hardship in many patients with cancer, even in high-income countries. The far-reaching consequences extend beyond the patients themselves to...
4.
Pham P, Schlander M, Eckford R, Hernandez-Villafuerte K, Ubels J
Patient
. 2023 Jun;
16(5):515-536.
PMID: 37368196
Background: Multiple studies have indicated a socioeconomic impact of cancer and cancer care on patients and their families. Existing instruments designed to measure this impact lack consensus in their conceptualization...
5.
Hernandez D, Cheng C, Hernandez-Villafuerte K, Schlander M
Oncol Res
. 2023 Jun;
30(4):173-185.
PMID: 37304413
Lung cancer is the most common cancer type worldwide and has the highest and second highest mortality rate for men and women respectively in Germany. Yet, the role of comorbid...
6.
Khan S, Hernandez-Villafuerte K, Hernandez D, Schlander M
Front Public Health
. 2023 Jan;
10:946544.
PMID: 36684975
Breast cancer (BC) is a heterogeneous disease representing a substantial economic burden. In order to develop policies that successfully decrease this burden, the factors affecting costs need to be fully...
7.
Muchadeyi M, Hernandez-Villafuerte K, Schlander M
BMC Med Res Methodol
. 2022 Nov;
22(1):303.
PMID: 36434521
Background: Health state utility values (HSUVs) are an essential input parameter to cost-utility analysis (CUA). Systematic literature reviews (SLRs) provide summarized information for selecting utility values from an increasing number...
8.
Hernandez-Villafuerte K, Zamora B, Feng Y, Parkin D, Devlin N, Towse A
Cost Eff Resour Alloc
. 2022 Oct;
20(1):56.
PMID: 36309687
Background: Empirical estimates of health system opportunity costs have been suggested as a basis for the cost-effectiveness threshold to use in Health Technology Assessment. Econometric methods have been used to...
9.
Hernandez D, Wagner F, Hernandez-Villafuerte K, Schlander M
J Gastrointest Cancer
. 2022 Apr;
54(2):391-407.
PMID: 35474568
Purpose: Pancreatic cancer is characterized by its high mortality, usually attributed to its diagnosis in already advanced stages. This article aims at presenting an overview of the economic burden of...
10.
Schlander M, Hernandez-Villafuerte K, Cheng C, Mestre-Ferrandiz J, Baumann M
Pharmacoeconomics
. 2021 Aug;
39(11):1243-1269.
PMID: 34368939
Background: Debate over the viability of the current commercial research and development (R&D) model is ongoing. A controversial theme is the cost of bringing a new molecular entity (NME) to...